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The use of PCR as a tool for the diagnostic virology and viral research 
laboratories has greatly increased in recent years, however the use of 
conventional PCR and amplicon detection systems can be a complex 
and relatively slow process that increases the risk of amplicon carry-
over contamination. Many conventional PCR systems are unsuited for, 
or unable to perform as accurate diagnostic and quantitative tools 
because viruses are present in such a diverse variety of patient 
tissues and in a broad range of concentrations. Traditional viral 
culture, while still the gold standard for the detection of many 
viruses, is lengthy, expensive and often subjective. In addition, 
successful isolation of infectious virus is variable and dependent upon 
appropriate cell lines, lengthy incubations and careful transport and 
storage of clinical specimens. Many of the disadvantages arising from 
the use of traditional assays for the detection of viruses have been 
overcome by the development of real-time PCR. The technology has 
continued to develop due to the introduction of several commercial 
thermal cycling platforms and the appearance of numerous specific 
and non-specific fluorogenic chemistries.  
 
For the purpose of this thesis, human virology was sectioned into 
three diagnostic divisions containing the synthetic viruses, the well 




proposes the hypothesis that real-time PCR could greatly improve 
upon traditional techniques for the detection, quantitation and 
characterisation of the members of these three divisions in both 
research and diagnostic environments. 
 
Conventional competitive quantitative PCR assays and a non-
oligoprobe real-time PCR assay were constructed to detect novel 
synthetic gene therapy vectors developed from retroviruses. When 
compared to oligoprobe-based real-time PCR, it was clear that 
conventional molecular assays, whilst improving upon traditional 
methods of viral culture and immunofluorescence, were slower, more 
complex, less versatile and were hindered by a limited dynamic 
range. Synthetic control templates were developed and an improved 
method of assaying these template preparations was devised. The 
controls were used to precisely optimise each assay, create quality 
assurance reagents and to construct external standard curves 
permitting the absolute quantitation of viral templates.  
 
Real-time PCR achieved several significant goals during the studies 
performed for this thesis. The new assays detected human 
enterovirus (HEV) and the emerging pathogen, human 
metapneumovirus (hMPV) which were both responsible for seasonal 
outbreaks of serious disease that would otherwise have gone 




of the Netherlands, as well as the first description of two validated 
rapid diagnostic RT-PCR assays which permitted the definitive 
classification of hMPV as a global pathogen of children and adults. 
Building upon its detection, an extensive molecular epidemiological 
study permitted the description of subtle differences between 
Australian and the more recently described international hMPV strains 
resulting in the classification of two distinct types of hMPV (A and B) 
and within these, four subtypes (A1, A2, B1 and B2).   
 
Real-time PCR rapidly detected, quantitated and genotyped herpes 
simplex viruses in a single reaction and determined the successful 
delivery of human and non-human genes by novel retroviral vectors 
in less time than any other phenotype detection assay. Additionally, 
these studies produced quantitative data which permitted the rapid 
calculation of transduction efficiency. Real-time PCR was able to 
quickly assess the efficiency of the PCR either in response to the 
titration of individual reaction components or as a result of 
amplification modifiers present within specimen extracts. The use of 
nucleotide sequencing studies ideally complemented earlier diagnostic 
studies of HEV and permitted the discrimination of pathogenic 
enterovirus 71. 
 
This thesis demonstrated that real-time PCR is more able to 




diagnostics than any other single method, and is now in a position to 
replace many of the traditional techniques still used by laboratories 
unfamiliar with the benefits of real-time PCR. The assays, techniques, 
reagents and publications resulting from these studies have benefited 
several areas of viral research and diagnostics and have improved the 
understanding of the role of real-time PCR in virology and of the 
technique in general, among the greater scientific community whilst 
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aa   Amino acid 
APV   Avian pneumovirus 
AR   Analytical reagent grade 
BHQ   Black hole quencher 
bRSV   Bovine respiratory syncytial virus 
CCD   Charge-coupled device 
Cftr (CFTR)   Cystic fibrosis transmembrane conductance regulator 
gene (protein) 
CT   Threshold cycle 
CP   Crossing point 
CVRU   Clinical Virology Research Unit 
DABCYL  4-[4’-dimethylamino-phenylazo]-benzene 
DIG   Digoxigenin 
dNTP   deoxyribonucleotides 
dsDNA  Double-stranded DNA 
ELAHA  Enzyme linked amplicon hybridisation assay 
ERV   Endogenous retrovirus 
EV71   Enterovirus 71 
FAM   6-carboxy-fluorescein 
FCS   Foetal calf serum 
FITC   Fluorescein isothiocyanate 
FMCA   Fluorescence melting curve analysis. 
FRET   Fluorescent resonance energy transfer 
Gfp  (GFP)   Green fluorescent protein gene (protein) 
HEV   Human enteroviruses 
hMPV   Human metapneumovirus 
hRSV   Human respiratory syncytial virus 
IC   Internal control 
LB   Luria Bertani medium 
LTR     Long terminal repeat 
LUX   Light-up upon extension 
MGB   Minor groove binding molecule 
MHC   Major histocompatibility complex 
MOI   Moiety of infection. 






mRNA Messenger RNA 
MSV   Murine Sarcoma Virus 
NDV   Newcastle disease virus 
NFQ   Non-fluorescent quencher 
NTR   Non-translated region 
ORF   Open reading frame 
bRSV   Bovine respiratory syncytial virus 
oRSV   Ovine respiratory syncytial virus 
PCR   Polymerase chain reaction 
PIV   Parainfluenza virus 
PNA   Peptide nucleic acid 
Poly(A)  Polyadenylated 
PVM   Pneumonia virus of mice 
qcPCR   Quantitative competitive PCR 
QHPS   Queensland Health Pathology Service 
RCH   Royal Children’s Hospital 
RCR     Replication competent retrovirus 
rRNA   Ribosomal RNA 
ROX   6-carboxy-N,N,N’,N’-tetramethylrhodamine 
RT   Reverse transcription 
RT-PCR    Reverse transcription PCR 
SASVRC  Sir Albert Sakzewski Virus Research Centre 
SNP   Single nucleotide polymorphisms  
SV   Simian virus 
TAMRA  6-carboxy-tetramethyl-rhodamine 
Taq   Thermus aquaticus 
TCID50  50% Tissue culture infective dose 
TD   Denaturation temperature 
TM   Melting temperature 
TMB   Tetramethylbenzidine 
TRTV   Turkey rhinotracheitis virus 
TV   Trypsin-versene solution 
UTR   Untranslated region 
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